Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Aug 12:13:973780.
doi: 10.3389/fphar.2022.973780. eCollection 2022.

Editorial: Kappa opioid receptors revealed: Disentangling the pharmacology to open up new therapeutic strategies

Wendy Margaret Walwyn  1 , Marta Valenza  2
Affiliations
Editorial

Editorial: Kappa opioid receptors revealed: Disentangling the pharmacology to open up new therapeutic strategies

Wendy Margaret Walwyn et al. Front Pharmacol. .
No abstract available

Keywords: G-protein; Kappa opioid receptor OR KOR OR KOPr OR KOP; addiction; biased agonism; dynorphins; opioids; pain; stress.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research TopicKappa Opioid receptors revealed: Disentangling the Pharmacology to Open Up New Therapeutic Strategies

References

    1. Bruchas M. R., Chavkin C. (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacol. Berl. 210 (2), 137–147. 10.1007/s00213-010-1806-y - DOI - PMC - PubMed
    1. Carlezon W. A., Jr., Krystal A. D. (2016). Kappa-opioid antagonists for psychiatric disorders: From bench to clinical trials. Depress. Anxiety 33 (10), 895–906. 10.1002/da.22500 - DOI - PMC - PubMed
    1. Domi E., Barbier E., Augier E., Augier G., Gehlert D., Barchiesi R., et al. (2018). Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders. Neuropsychopharmacology 43 (9), 1805–1812. 10.1038/s41386-018-0015-y - DOI - PMC - PubMed
    1. Jackson K. J., Jackson A., Carroll F. I., Damaj M. I. (2015). Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 97, 270–274. 10.1016/j.neuropharm.2015.05.023 - DOI - PMC - PubMed
    1. Liu S. S., Pickens S., Burma N. E., Ibarra-Lecue I., Yang H., Xue L., et al. (2019). Kappa opioid receptors drive a tonic aversive component of chronic pain. J. Neurosci. 39 (21), 4162–4178. 10.1523/JNEUROSCI.0274-19.2019 - DOI - PMC - PubMed

Publication types

LinkOut - more resources